SCHEMBL19087492

SCHEMBL19087492

c1ccc2oc(-c3ccc4[nH]c(-c5ccc6ncoc6c5)nc4c3)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.43
DYRK1A Q13627 2/20 0.42
ADRA2A P08913 1/20 0.41
DDX3X O00571 1/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
MAOB P27338 2/20 0.39
MAOA P21397 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PTPRC P08575 1/20 0.38
PTPN1 P18031 1/20 0.38
POLB P06746 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
MAPT P10636 3/20 0.37
HPGD P15428 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20469630 0.92 ADRA2A (0.45) ALOX5DYRK1AADRA2ADDX3XNPC1
SCHEMBL20022978 0.92 DYRK1A (0.43) ALOX5DYRK1AADRA2ADDX3XNPC1
SCHEMBL22917376 0.87 ADRA2A (0.44) ALOX5DYRK1AADRA2ADDX3XNPC1
SCHEMBL18671143 0.81 ESR1 (0.43) DYRK1ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL23871266 0.81 NPC1 (0.56) DYRK1ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL20966294 0.76 RIPK1 (0.47) DYRK1A
SCHEMBL14860721 0.74 KDM4E (0.52) ADRA2ADDX3XNPC1RAB9AMAOB
SCHEMBL20017371 0.73 DYRK1A (0.45) ALOX5DYRK1AADRA2ANPC1RAB9A
SCHEMBL19203362 0.73 PRMT3 (0.46) ALOX5DYRK1AADRA2ANPC1RAB9A
SCHEMBL19557533 0.73 NPC1 (0.53) DYRK1ANPC1RAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141101-A1 PDE4 INHIBITOR COMPOUND AND MEDICAL USE THEREOF SUZHOU LONGBOTAI PHARMACEUTICALS CO., LTD. (CN) 2023-05-11 US disclosed
US-20170190735-A1 DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES AGENSYS, INC. (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141101-A1 PDE4 INHIBITOR COMPOUND AND MEDICAL USE THEREOF PDE4B, PDE4A, PDE12 ALOX5 1816/4885DYRK1A 813/4885ADRA2A 1145/4885
US-20170190735-A1 DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES DDOST, VIP, THPO ALOX5 2336/4885DYRK1A 2342/4885ADRA2A 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.